Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pleural Neoplasms | 31 | 2024 | 609 | 6.970 |
Why?
|
Mesothelioma | 30 | 2024 | 807 | 6.280 |
Why?
|
Lung Neoplasms | 43 | 2024 | 13382 | 2.420 |
Why?
|
Neoplasm Staging | 24 | 2024 | 11121 | 1.380 |
Why?
|
Solitary Pulmonary Nodule | 6 | 2020 | 278 | 1.290 |
Why?
|
Mediastinal Neoplasms | 4 | 2022 | 401 | 1.250 |
Why?
|
Pneumonectomy | 13 | 2021 | 1119 | 1.190 |
Why?
|
Pleural Diseases | 3 | 2015 | 137 | 1.160 |
Why?
|
Thoracic Surgery, Video-Assisted | 2 | 2020 | 285 | 0.970 |
Why?
|
Lung Diseases, Interstitial | 7 | 2024 | 918 | 0.750 |
Why?
|
Tomography, X-Ray Computed | 30 | 2024 | 20571 | 0.730 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 9 | 2023 | 5315 | 0.710 |
Why?
|
Diagnostic Imaging | 7 | 2019 | 3530 | 0.680 |
Why?
|
Diffusion Magnetic Resonance Imaging | 5 | 2024 | 2791 | 0.670 |
Why?
|
Multiple Pulmonary Nodules | 3 | 2020 | 173 | 0.660 |
Why?
|
Bronchoscopy | 3 | 2022 | 909 | 0.610 |
Why?
|
Anesthesia, General | 3 | 2022 | 1174 | 0.580 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2016 | 474 | 0.490 |
Why?
|
Benchmarking | 1 | 2021 | 1045 | 0.470 |
Why?
|
Arthritis, Rheumatoid | 7 | 2024 | 3763 | 0.470 |
Why?
|
Bronchial Fistula | 1 | 2013 | 83 | 0.440 |
Why?
|
Thoracic Neoplasms | 3 | 2019 | 267 | 0.390 |
Why?
|
Radiology | 5 | 2024 | 2113 | 0.390 |
Why?
|
Magnetic Resonance Imaging | 10 | 2021 | 36429 | 0.350 |
Why?
|
Unnecessary Procedures | 1 | 2013 | 415 | 0.350 |
Why?
|
Surgery, Computer-Assisted | 2 | 2015 | 1007 | 0.330 |
Why?
|
Tumor Burden | 6 | 2020 | 1893 | 0.330 |
Why?
|
Bronchiectasis | 2 | 2022 | 139 | 0.300 |
Why?
|
Aged | 45 | 2024 | 169310 | 0.300 |
Why?
|
Humans | 96 | 2024 | 761572 | 0.300 |
Why?
|
Anesthesia | 1 | 2018 | 1595 | 0.290 |
Why?
|
Myxoma | 1 | 2008 | 114 | 0.280 |
Why?
|
Aged, 80 and over | 22 | 2024 | 58986 | 0.280 |
Why?
|
Middle Aged | 51 | 2024 | 220920 | 0.270 |
Why?
|
Primary Prevention | 1 | 2013 | 1186 | 0.260 |
Why?
|
Airway Obstruction | 2 | 2022 | 661 | 0.240 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 3201 | 0.240 |
Why?
|
Heart Neoplasms | 1 | 2008 | 362 | 0.230 |
Why?
|
Male | 54 | 2024 | 360842 | 0.230 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7391 | 0.230 |
Why?
|
Sensitivity and Specificity | 10 | 2024 | 14666 | 0.220 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 8002 | 0.220 |
Why?
|
Pulmonary Artery | 4 | 2014 | 1927 | 0.220 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2019 | 297 | 0.220 |
Why?
|
Female | 56 | 2024 | 392686 | 0.210 |
Why?
|
Positron-Emission Tomography | 8 | 2022 | 6485 | 0.210 |
Why?
|
Lung Transplantation | 2 | 2012 | 1310 | 0.210 |
Why?
|
Internship and Residency | 1 | 2023 | 5882 | 0.210 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4026 | 0.210 |
Why?
|
Contrast Media | 8 | 2024 | 5311 | 0.200 |
Why?
|
Prognosis | 11 | 2024 | 29629 | 0.200 |
Why?
|
Pneumothorax | 2 | 2020 | 386 | 0.200 |
Why?
|
Hyperthermia, Induced | 2 | 2018 | 417 | 0.200 |
Why?
|
CA-125 Antigen | 1 | 2024 | 281 | 0.190 |
Why?
|
Public Opinion | 2 | 2022 | 484 | 0.190 |
Why?
|
Lung | 8 | 2022 | 10002 | 0.180 |
Why?
|
Angiography | 3 | 2011 | 1595 | 0.180 |
Why?
|
Adult | 34 | 2024 | 221203 | 0.180 |
Why?
|
Intraoperative Care | 2 | 2015 | 767 | 0.170 |
Why?
|
Atrial Appendage | 1 | 2024 | 283 | 0.170 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2915 | 0.170 |
Why?
|
Pulmonary Embolism | 5 | 2014 | 2567 | 0.170 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 3597 | 0.170 |
Why?
|
Emphysema | 1 | 2022 | 238 | 0.170 |
Why?
|
Postoperative Complications | 2 | 2015 | 15633 | 0.170 |
Why?
|
Retrospective Studies | 22 | 2022 | 80646 | 0.170 |
Why?
|
Cisplatin | 2 | 2018 | 1652 | 0.170 |
Why?
|
Iohexol | 2 | 2012 | 204 | 0.170 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2012 | 3359 | 0.150 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 326 | 0.150 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 15266 | 0.150 |
Why?
|
Motion | 2 | 2020 | 779 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9280 | 0.150 |
Why?
|
Reproducibility of Results | 11 | 2024 | 20099 | 0.150 |
Why?
|
Mass Screening | 1 | 2013 | 5428 | 0.150 |
Why?
|
Survival Rate | 7 | 2024 | 12725 | 0.150 |
Why?
|
Education, Distance | 1 | 2021 | 261 | 0.150 |
Why?
|
Dermatitis | 1 | 2019 | 202 | 0.150 |
Why?
|
Students, Medical | 2 | 2021 | 1936 | 0.140 |
Why?
|
Reference Standards | 1 | 2021 | 1003 | 0.140 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 629 | 0.140 |
Why?
|
Pulmonary Emphysema | 4 | 2016 | 684 | 0.140 |
Why?
|
Prospective Studies | 8 | 2024 | 54426 | 0.140 |
Why?
|
Expert Testimony | 1 | 2019 | 364 | 0.140 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2022 | 515 | 0.130 |
Why?
|
Follow-Up Studies | 6 | 2023 | 39107 | 0.130 |
Why?
|
Biopsy | 2 | 2022 | 6766 | 0.130 |
Why?
|
Respiration | 2 | 2020 | 1657 | 0.120 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2020 | 740 | 0.120 |
Why?
|
Diagnosis, Differential | 5 | 2024 | 12975 | 0.120 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 423 | 0.120 |
Why?
|
Neoplasms | 2 | 2021 | 22173 | 0.120 |
Why?
|
Positive-Pressure Respiration | 1 | 2018 | 639 | 0.110 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 899 | 0.110 |
Why?
|
Clinical Clerkship | 1 | 2020 | 564 | 0.110 |
Why?
|
Cardiac Tamponade | 1 | 2005 | 175 | 0.110 |
Why?
|
Deoxycytidine | 1 | 2018 | 877 | 0.110 |
Why?
|
Perfusion Imaging | 1 | 2015 | 196 | 0.110 |
Why?
|
Ductus Arteriosus, Patent | 1 | 2005 | 217 | 0.110 |
Why?
|
Combined Modality Therapy | 5 | 2018 | 8528 | 0.110 |
Why?
|
Pleurisy | 1 | 2013 | 54 | 0.100 |
Why?
|
Algorithms | 3 | 2021 | 14032 | 0.100 |
Why?
|
Bronchi | 1 | 2016 | 845 | 0.100 |
Why?
|
Consensus | 2 | 2019 | 3123 | 0.100 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2017 | 710 | 0.100 |
Why?
|
Lung Volume Measurements | 1 | 2013 | 375 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2510 | 0.100 |
Why?
|
Radiotherapy | 1 | 2019 | 1499 | 0.100 |
Why?
|
Neoadjuvant Therapy | 2 | 2015 | 2827 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 2017 | 791 | 0.100 |
Why?
|
Pandemics | 2 | 2023 | 8656 | 0.100 |
Why?
|
Artifacts | 1 | 2020 | 1911 | 0.090 |
Why?
|
Adenocarcinoma | 2 | 2019 | 6346 | 0.090 |
Why?
|
Image Enhancement | 3 | 2012 | 2885 | 0.090 |
Why?
|
Registries | 3 | 2018 | 8224 | 0.090 |
Why?
|
Mycobacterium | 1 | 2012 | 251 | 0.090 |
Why?
|
Radiography, Thoracic | 3 | 2020 | 1302 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1745 | 0.090 |
Why?
|
Young Adult | 8 | 2024 | 59255 | 0.090 |
Why?
|
Logistic Models | 4 | 2022 | 13255 | 0.090 |
Why?
|
Bronchopulmonary Sequestration | 1 | 2010 | 43 | 0.090 |
Why?
|
Radiography, Interventional | 2 | 2015 | 1121 | 0.090 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 1972 | 0.080 |
Why?
|
Incidental Findings | 1 | 2014 | 697 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2016 | 3204 | 0.080 |
Why?
|
Asbestos | 1 | 2011 | 251 | 0.080 |
Why?
|
Body Burden | 1 | 2009 | 158 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2057 | 0.080 |
Why?
|
Gadolinium DTPA | 1 | 2012 | 823 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12463 | 0.080 |
Why?
|
Radiation Dosage | 2 | 2014 | 1958 | 0.080 |
Why?
|
Iodine | 1 | 2010 | 288 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2557 | 0.070 |
Why?
|
Tracheal Diseases | 1 | 2008 | 118 | 0.070 |
Why?
|
Pleural Effusion, Malignant | 1 | 2009 | 106 | 0.070 |
Why?
|
Mesentery | 1 | 2008 | 202 | 0.070 |
Why?
|
Pulmonary Valve Stenosis | 1 | 2008 | 164 | 0.070 |
Why?
|
Bronchial Diseases | 1 | 2008 | 150 | 0.070 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2009 | 302 | 0.070 |
Why?
|
Immune Tolerance | 1 | 2016 | 2302 | 0.070 |
Why?
|
Fibromatosis, Aggressive | 1 | 2008 | 126 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2024 | 4671 | 0.070 |
Why?
|
Palliative Care | 3 | 2021 | 3598 | 0.070 |
Why?
|
Cohort Studies | 6 | 2021 | 41493 | 0.070 |
Why?
|
Phlebography | 1 | 2008 | 326 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13642 | 0.070 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15843 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11076 | 0.070 |
Why?
|
Aneurysm, False | 1 | 2008 | 255 | 0.070 |
Why?
|
Flow Cytometry | 1 | 2016 | 5869 | 0.060 |
Why?
|
Radiographic Image Enhancement | 1 | 2010 | 876 | 0.060 |
Why?
|
Radiography | 2 | 2013 | 6965 | 0.060 |
Why?
|
Proteoglycans | 1 | 2009 | 803 | 0.060 |
Why?
|
Treatment Outcome | 8 | 2021 | 64684 | 0.060 |
Why?
|
Radiation Protection | 1 | 2009 | 424 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2016 | 5247 | 0.060 |
Why?
|
Dyspnea | 1 | 2013 | 1347 | 0.060 |
Why?
|
Thoracic Surgical Procedures | 1 | 2009 | 350 | 0.060 |
Why?
|
Smoking | 2 | 2024 | 9053 | 0.060 |
Why?
|
Risk Factors | 9 | 2022 | 74213 | 0.060 |
Why?
|
Pulmonary Medicine | 1 | 2007 | 221 | 0.060 |
Why?
|
Respiratory Tract Infections | 1 | 2012 | 1010 | 0.060 |
Why?
|
Breast Diseases | 1 | 2007 | 442 | 0.060 |
Why?
|
Biopsy, Needle | 1 | 2009 | 1626 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2021 | 4811 | 0.060 |
Why?
|
Software | 1 | 2017 | 4434 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2009 | 2341 | 0.050 |
Why?
|
Survival Analysis | 2 | 2016 | 10090 | 0.050 |
Why?
|
Pelvis | 1 | 2008 | 733 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3877 | 0.050 |
Why?
|
Reoperation | 1 | 2013 | 4303 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2012 | 1529 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3466 | 0.050 |
Why?
|
Lung Diseases | 1 | 2013 | 1909 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5821 | 0.050 |
Why?
|
GPI-Linked Proteins | 1 | 2024 | 470 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Decision Support Systems, Clinical | 1 | 2011 | 1175 | 0.050 |
Why?
|
United States | 4 | 2019 | 72335 | 0.050 |
Why?
|
Regression Analysis | 1 | 2012 | 6344 | 0.050 |
Why?
|
Ethanol | 1 | 2008 | 1324 | 0.050 |
Why?
|
Mucin-5B | 1 | 2022 | 148 | 0.050 |
Why?
|
Sarcoidosis | 1 | 2007 | 521 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2220 | 0.050 |
Why?
|
Peritoneal Neoplasms | 1 | 2008 | 711 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1222 | 0.050 |
Why?
|
Thrombosis | 1 | 2005 | 2942 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11742 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7581 | 0.050 |
Why?
|
Observer Variation | 3 | 2014 | 2606 | 0.040 |
Why?
|
Risk Assessment | 3 | 2012 | 23996 | 0.040 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2010 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2011 | 1923 | 0.040 |
Why?
|
Biopsy, Fine-Needle | 2 | 2016 | 1118 | 0.040 |
Why?
|
Case-Control Studies | 4 | 2022 | 22176 | 0.040 |
Why?
|
Lower Extremity | 1 | 2008 | 1202 | 0.040 |
Why?
|
Vital Capacity | 2 | 2016 | 971 | 0.040 |
Why?
|
Life Style | 2 | 2022 | 3917 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 2008 | 1159 | 0.040 |
Why?
|
X-Rays | 1 | 2020 | 307 | 0.040 |
Why?
|
Gadolinium | 1 | 2024 | 960 | 0.040 |
Why?
|
Foundations | 1 | 2019 | 95 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2651 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2016 | 10194 | 0.040 |
Why?
|
Indocyanine Green | 1 | 2020 | 233 | 0.040 |
Why?
|
Adolescent | 5 | 2024 | 88324 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 243 | 0.040 |
Why?
|
Disease Progression | 3 | 2022 | 13510 | 0.040 |
Why?
|
Venous Thrombosis | 1 | 2008 | 1303 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2020 | 6815 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 562 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9420 | 0.040 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2578 | 0.040 |
Why?
|
Telomere | 1 | 2024 | 943 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2009 | 1896 | 0.040 |
Why?
|
Forced Expiratory Volume | 2 | 2016 | 1814 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6484 | 0.040 |
Why?
|
Curriculum | 2 | 2021 | 3743 | 0.040 |
Why?
|
Bronchial Arteries | 1 | 2016 | 21 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1648 | 0.040 |
Why?
|
Total Lung Capacity | 1 | 2016 | 149 | 0.030 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2019 | 455 | 0.030 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2021 | 732 | 0.030 |
Why?
|
Graft vs Host Disease | 1 | 2008 | 3029 | 0.030 |
Why?
|
Databases, Factual | 2 | 2024 | 7967 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2008 | 2751 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 9002 | 0.030 |
Why?
|
Remission Induction | 1 | 2019 | 2397 | 0.030 |
Why?
|
Pain | 1 | 2008 | 5073 | 0.030 |
Why?
|
Autoantibodies | 1 | 2022 | 2116 | 0.030 |
Why?
|
Mediastinum | 1 | 2014 | 267 | 0.030 |
Why?
|
Methotrexate | 1 | 2019 | 1719 | 0.030 |
Why?
|
Mycobacterium avium Complex | 1 | 2012 | 60 | 0.030 |
Why?
|
Area Under Curve | 1 | 2016 | 1638 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4853 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2022 | 5790 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 2017 | 980 | 0.020 |
Why?
|
Boston | 2 | 2015 | 9326 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2005 | 1835 | 0.020 |
Why?
|
Time Factors | 3 | 2020 | 39970 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9646 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4915 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2009 | 17904 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2161 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5672 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 1372 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1784 | 0.020 |
Why?
|
Prevalence | 3 | 2012 | 15732 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2019 | 2803 | 0.020 |
Why?
|
Computer Graphics | 1 | 2011 | 340 | 0.020 |
Why?
|
Fibromatosis, Abdominal | 1 | 2008 | 21 | 0.020 |
Why?
|
ROC Curve | 1 | 2016 | 3579 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3848 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2644 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2021 | 2529 | 0.020 |
Why?
|
Diaphragm | 1 | 2010 | 351 | 0.020 |
Why?
|
Lod Score | 1 | 2009 | 600 | 0.020 |
Why?
|
Comorbidity | 2 | 2016 | 10508 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3416 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 1682 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2015 | 2898 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4652 | 0.020 |
Why?
|
Incidence | 2 | 2019 | 21355 | 0.020 |
Why?
|
Vinblastine | 1 | 2008 | 488 | 0.020 |
Why?
|
Massachusetts | 2 | 2011 | 8830 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4575 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3267 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2015 | 3514 | 0.020 |
Why?
|
Spirometry | 1 | 2009 | 929 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 3778 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4319 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2011 | 1400 | 0.010 |
Why?
|
Siblings | 1 | 2007 | 825 | 0.010 |
Why?
|
Kinetics | 1 | 2011 | 6374 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2008 | 857 | 0.010 |
Why?
|
Doxorubicin | 1 | 2008 | 2224 | 0.010 |
Why?
|
Pedigree | 1 | 2009 | 4542 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12059 | 0.010 |
Why?
|
Genetic Testing | 1 | 2014 | 3537 | 0.010 |
Why?
|
Phenotype | 2 | 2009 | 16592 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2007 | 21017 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2021 | 9031 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6241 | 0.010 |
Why?
|
Pain Measurement | 1 | 2008 | 3551 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2007 | 2644 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9469 | 0.010 |
Why?
|
Animals | 2 | 2015 | 168467 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2009 | 15936 | 0.010 |
Why?
|
Mice | 1 | 2009 | 81533 | 0.000 |
Why?
|